Skip to main content

Table 3 Comparison between results of neurocognitive scales in both groups

From: Relation of serum level of tumor necrosis factor-alpha to cognitive functions in patients with Parkinson’s disease

Mean ± SD Patients group
(n = 30)
Control group
(n = 30)
p-value
ACE-III 81.40 ± 5.957 94.33 ± 3.066  < 0.001**
Attention ACE 17.13 ± 0.900 17.53 ± 0.571 0.044*
Memory ACE 19.63 ± 4.115 24.30 ± 1.119  < 0.001**
Verbal fluency ACE 6.87 ± 2.609 12.67 ± 0.959  < 0.001**
Language ACE 24.93 ± 1.311 25.23 ± 0.679 0.272
Visuospatial ACE 13.33 ± 1.863 15.23 ± 0.817  < 0.001**
Trail making test B 239.14 ± 53.728 103.10 ± 24.669  < 0.001**
  1. ACE-III Addenbrooke’s Cognitive Examination
  2. *Significant, ** highly significant